Texas is currently home to 4880 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
Recruiting
This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
06/26/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Avian Influenza
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Recruiting
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Dallas Heart and Vascular Consultants, PA, Duncanville, Texas
Conditions: Hypertension
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Recruiting
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Dallas Heart and Vascular Consultants, PA, Duncanville, Texas
Conditions: Hypertension, Overweight or Obesity
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Recruiting
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: South Texas Accelerated Research Therapeutics, San Antonio, Texas
Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Recruiting
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Investigative Site US052, Arlington, Texas
Conditions: Hidradenitis Suppurativa (HS)
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Recruiting
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness o... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/26/2025
Locations: Takeda Site 18, San Antonio, Texas
Conditions: Idiopathic Hypersomnia
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
Recruiting
This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone. This study has a crossover period, where subjects on st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Site 03, Fort Worth, Texas
Conditions: Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/26/2025
Locations: Sl0044 50562, Allen, Texas
Conditions: Systemic Lupus Erythematosus
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Recruiting
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/26/2025
Locations: Cullinan Investigative Site, Plano, Texas
Conditions: SLE, SLE (Systemic Lupus)
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Abilene, TX, Abilene, Texas
Conditions: Diabetic Macular Edema (DME)
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Recruiting
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Ben Taub General Hospital, Houston, Texas
Conditions: HER2-positive Metastatic Breast Cancer
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/26/2025
Locations: Dell Children'S Medical Group, Austin, Texas
Conditions: NonSegmental Vitiligo